SFI
CLSD

Susquehanna Fundamental Investments’s Clearside Biomedical CLSD Stock Holding History

Susquehanna Fundamental Investments’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,957
Closed -$176K – 1491
2021
Q3 		$176K Buy
+1,957
New +$173K ﹤0.01% 1558

Other funds holding CLSD

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna Fundamental Investments's CLSD Position: Q4 2021 in Review

Susquehanna Fundamental Investments sold out of Clearside Biomedical (CLSD) in Q4 2021, closing a stake of 1,957 shares — an estimated $176K sold.

Susquehanna Fundamental Investments first reported a position in CLSD in Q3 2021 and held it in 1 quarter. The position peaked at $176K in Q3 2021. 67 funds tracked by Wall St. Rank hold CLSD as of Q4 2021.

  • Susquehanna Fundamental Investments reported no remaining Clearside Biomedical position as of Q4 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 1,957 Clearside Biomedical shares in Q4 2021, an estimated $176K.
  • Susquehanna Fundamental Investments first reported a position in Clearside Biomedical in Q3 2021 and held it in 1 quarter.
  • Susquehanna Fundamental Investments's Clearside Biomedical position peaked at $176K in Q3 2021.
  • 67 funds tracked by Wall St. Rank held Clearside Biomedical as of Q4 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2021, filed 14 Feb 2022.